Key result
AF at cardiac sarcoidosis diagnosis is linked to ~96% higher risk of death or heart failure hospitalization.
Why the study?
The prognostic value of the presence of atrial fibrillation in patients at the time of cardiac sarcoidosis diagnosis was unknown.
Does the presence of atrial fibrillation at the time of diagnosis increase the risk of all-cause death and heart failure hospitalization in patients with cardiac sarcoidosis?
Observational (n=445)
Yes
Does the presence of atrial fibrillation at the time of diagnosis increase the risk of all-cause death and heart failure hospitalization in patients with cardiac sarcoidosis?
Hazard Ratio: 1.96 (95% CI 1.05–3.65)
p-value: p=0.035
The presence of atrial fibrillation at the time of cardiac sarcoidosis diagnosis is an independent predictor of all-cause mortality and heart failure hospitalization.
AF at cardiac sarcoidosis diagnosis was associated with higher death and HF hospitalization risk; extends prognostic stratification but leaves causal implications open.
Aims The prognostic value of the presence of atrial fibrillation (AF) in patients at the time of cardiac sarcoidosis (CS) diagnosis is unknown. This study aimed to investigate the association between AF at the time of CS diagnosis and patient prognosis. Methods and results This study is a post-hoc analysis of Illustration of the Management and Prognosis of Japanese Patients with CS, a multicentre, retrospective observational study that evaluated the clinical characteristics and prognosis of patients with CS. The primary endpoint was the combined endpoint of all-cause death and hospitalization due to heart failure. After excluding patients with missing data about AF status, 445 patients (62 ± 11 years, 36% males) diagnosed with CS according to the Japanese current diagnostic guideline were analysed. Compared to patients without AF, patients with AF (n = 46, 10%) had higher levels of brain natriuretic peptide and a higher prevalence of heart failure hospitalizations. During a median follow-up period of 3.2 years (interquartile range, 1.7–5.8 years), 80 primary endpoints were observed. Kaplan–Meier curve analysis indicated that concomitant AF at the time of diagnosis was significantly associated with a high incidence of primary endpoints (log-rank P = 0.002). This association was retained after adjusting for known risk factors including log-transformed brain natriuretic peptide levels and left ventricular ejection fractions [hazard ratio, 1.96 (95% confidence interval, 1.05–3.65); P = 0.035]. Conclusion The presence of AF at the time of CS diagnosis is associated with higher incidence of all-cause death and heart failure hospitalization.
No takes yet. Share an insight, caveat, or question.
Fujimoto et al. (2023) conducted an observational in Cardiac sarcoidosis (n=445). Atrial fibrillation at the time of diagnosis vs. Absence of atrial fibrillation was evaluated on Combined endpoint of all-cause death and hospitalization due to heart failure (HR 1.96, 95% CI 1.05-3.65, p=0.035). The presence of atrial fibrillation at the time of cardiac sarcoidosis diagnosis was independently associated with a higher incidence of all-cause death and heart failure hospitalization (HR 1.96).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: